Size-based separation methods of circulating tumor cells

Hao, Si Jie; Wan, Yuan; Xia, Yiqiu; Zou, Xin; Zheng, Shan

doi:10.1016/j.addr.2018.01.002

Cited by 175 publications

(140 citation statements)

References 197 publications

Supporting

Mentioning

124

Contrasting

Unclassified

Order By: Relevance

“…There are several filter-based systems for capturing CTCs. [50][51][52] We did not directly compare the performance between the MCA system and other filter-based methods but preclinical and clinical data support that the MCA system is comparable to other systems and it may have an advantage over others in NSCLC. It was previously shown that in spike-in experiments MCA system could recover more than 80% of various lung cancer cell lines with the mean size of 12.5 μm and more including high VM-expressing cell lines, such as PC-14.…”

Section: Discussionmentioning

confidence: 99%

Detection of AXL expression in circulating tumor cells of lung cancer patients using an automated microcavity array system

et al. 2020

View full text Add to dashboard Cite

Noninvasive diagnostics using circulating tumor cells (CTCs) are expected to be useful for decision making in precision cancer therapy. AXL, a receptor tyrosine kinase is associated with tumor progression, epithelial‐to‐mesenchymal transition (EMT), and drug resistance, and is a potential therapeutic target. However, the epithelial markers generally used for CTC detection may be not enough to detect AXL‐expressing CTCs due to EMT. Here, we evaluated the detection of AXL‐expressing CTCs using the mesenchymal marker vimentin with a microcavity array system. To evaluate the recovery of cancer cells, spike‐in experiments were performed using cell lines with varying cytokeratin (CK) or vimentin (VM) expression levels. With high CK and low VM‐expressing cell lines, PC‐9 and HCC827, the recovery rate of AXL‐expressing cancer cells was 1%‐17% using either CK or VM as markers. Whereas, with low CK and high VM‐expressing cell lines, MDA‐MB231 and H1299, it was 52%‐75% using CK and 72%‐88% using VM as a marker. For clinical evaluation, peripheral blood was collected from 20 non–small cell lung cancer patients and CTCs were detected using CK or VM as markers in parallel. Significantly more AXL‐expressing single CTCs were detected in VM‐positive than CK‐positive CTCs (P < .001). Furthermore, CTC clusters were identified only among VM‐positive CTCs in 20% of patients. Patients with one or more prior treatments harbored significantly more VM‐positive AXL‐expressing CTCs, suggesting the involvement of these CTCs in drug resistance. These results indicate the necessity of integrating mesenchymal markers with CTC detection and this should be further evaluated clinically.

show abstract

Section: Discussionmentioning

confidence: 99%

Detection of AXL expression in circulating tumor cells of lung cancer patients using an automated microcavity array system

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Recently, there have been commercially available reagents and platforms based on the above different principles for separating GC-and CRC-CTCs, including density gradient centrifugation (Ficoll-Pauqe R ; OncoQuick R ; RosetteSep R CTC), microfiltration (ScreenCell R ; ISET R ), inertial focusing (Vortex R ), and electrophoresis (DEPArray R ) (41). The most common biophysical CTCs enrichment technology is size-based microfiltration, which assumes that CTCs can be isolated from blood cells due to their larger volume and more rigid shape, and this technology has been improved by the introduction of nano to micron-sized filter pores (42). Currently, new lab-on-a-chip microfluidics devices have gradually appeared and significantly improved the GC-and CRC-CTCs yields compared with the conventional membrane microfiltration and EpCAM-based immunoaffinity assays (43,44).…”

Section: Biophysical Property-based Technologies Of Ctcsmentioning

confidence: 99%

Circulating Tumor Cells in Gastrointestinal Cancers: Current Status and Future Perspectives

et al. 2019

View full text Add to dashboard Cite

“…3 Cultures of patient-derived CTCs can be most helpful for drug-resistance detection, and make it possible for personalized anticancer-agent screening ( Figure 2). 10,13 Figure 1 Timeline of PubMed entries. Notes: Search criteria included "nanotechnology" AND "CTCs", "nano" AND "CTCs", and "nano" AND "circulating tumor cells" to determine number of publications (columns).…”

Section: Introductionmentioning

confidence: 99%

“…126 This technology has become mainstream in CTC enrichment and detection, due to its cost-effectiveness, miniaturization, and improvement in efficiency, since it can be integrated into other techniques. 13,127 The development of the majority of current microchip platforms is based on magnetic force, affinity, size, or other physical properties. 128 Two types of microfluidic devices are used for CTC detection: the immunomagnetic-based method for CTC detection (eg, CTC chip), and antibody labeling combined with physical isolation (Figure 5), which can consist of different materials like silicon, glass, or thermopolymer.…”

mentioning

confidence: 99%

<p>Is small smarter? Nanomaterial-based detection and elimination of circulating tumor cells: current knowledge and perspectives</p>

Gribko

Künzel

Wünsch

et al. 2019

IJN

View full text Add to dashboard Cite

Circulating tumor cells (CTCs) are disseminated cancer cells. The occurrence and circulation of CTCs seem key for metastasis, still the major cause of cancer-associated deaths. As such, CTCs are investigated as predictive biomarkers. However, due to their rarity and heterogeneous biology, CTCs’ practical use has not made it into the clinical routine. Clearly, methods for the effective isolation and reliable detection of CTCs are urgently needed. With the development of nanotechnology, various nanosystems for CTC isolation and enrichment and CTC-targeted cancer therapy have been designed. Here, we summarize the relationship between CTCs and tumor metastasis, and describe CTCs’ unique properties hampering their effective enrichment. We comment on nanotechnology-based systems for CTC isolation and recent achievements in microfluidics and lab-on-a-chip technologies. We discuss recent advances in CTC-targeted cancer therapy exploiting the unique properties of nanomaterials. We conclude by introducing developments in CTC-directed nanosystems and other advanced technologies currently in (pre)clinical research.

show abstract

Size-based separation methods of circulating tumor cells

Cited by 175 publications

References 197 publications

Detection of AXL expression in circulating tumor cells of lung cancer patients using an automated microcavity array system

Detection of AXL expression in circulating tumor cells of lung cancer patients using an automated microcavity array system

Circulating Tumor Cells in Gastrointestinal Cancers: Current Status and Future Perspectives

<p>Is small smarter? Nanomaterial-based detection and elimination of circulating tumor cells: current knowledge and perspectives</p>

Contact Info

Product

Resources

About